Fatty liver disease: Disparate predictive ability for cardiometabolic risk and all-cause mortality

World Journal of Gastroenterology

Volumn 21, Issue 48, 2015, Pages 13555-13565

  Onat, Altan ^a   Can, Günay ^a   Kaya, Ayşem ^b   Akbaş, Tuʇba ^c   Özpamuk Karadeniz, Fatma ^d   Şimşek, Bariş ^e   Çakir, Hakan ^f   Yüksel, Hüsniye ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Department of Internal Medicine   (Turkey)

^d Bal kligol State Hospital   (Turkey)

^e DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^f Darica Farabi State Hospital   (Turkey)

Author keywords

All cause death; Coronary heart disease; Hepatic steatosis; Metabolic syndrome; Turkish adult risk factor study

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SEX HORMONE BINDING GLOBULIN; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGE; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIET RESTRICTION; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ASSOCIATION; FATTY LIVER; FATTY LIVER INDEX; FEMALE; FOLLOW UP; HUMAN; INCIDENTAL FINDING; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PROGNOSIS; PROGNOSTIC ASSESSMENT; PROSPECTIVE STUDY; SEX RATIO; SMOKING; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; AGED; ALGORITHM; CAUSE OF DEATH; CHI SQUARE DISTRIBUTION; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; INCIDENCE; KAPLAN MEIER METHOD; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TURKEY;

ADULT; AGED; ALGORITHMS; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TURKEY;

EID: 84953340928     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i48.13555     Document Type: Article

References (41)

1. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10: 330-344 [PMID: 23507799 DOI: 10.1038/nrgastro.2013.41]
2. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 27-38 [PMID: 17690317 DOI: 10.1161/ATVBAHA.107.147538]
3. Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007; 30: 2940-2944 [PMID: 17666460 DOI: 10.2337/dc07-0792]
4. Yamada T, Fukatsu M, Suzuki S, Wada T, Yoshida T, Joh T. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010; 25: 352-356 [PMID: 19817963 DOI: 10.1111/j.1440-1746.2009.05998.x]
5. Sung KC, Jeong WS, Wild SH, Byrne CD. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care 2012; 35: 717-722 [PMID: 22338098 DOI: 10.2337/dc11-1853]
6. Loria P, Lonardo A, Bellentani S, Day CP, Marchesini G, Carulli N. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis 2007; 17: 684-698 [PMID: 17560098 DOI: 10.1016/j.numecd.2007.01.007]
7. Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, Erbel R, Blankstein R, Feldman T, Al-Mallah MH, Santos RD, Budoff MJ, Nasir K. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 2013; 230: 258-267 [PMID: 24075754 DOI: 10.1016/j.atherosclerosis.2013.07.052]
8. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350 [PMID: 20879883 DOI: 10.1056/NEJMra0912063]
9. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012; 10: 646-650 [PMID: 22245962 DOI: 10.1016/j.cgh.2011.12.039]
10. Targher G. Elevated serum gamma-glutamyltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and cancer - a narrative review. Clin Chem Lab Med 2010; 48: 147-157 [PMID: 19943812 DOI: 10.1515/CCLM.2010.031]
11. Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? J Hepatol 2011; 54: 1020-1029 [PMID: 21145850 DOI: 10.1016/j.jhep.2010.11.007]
12. Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol 2012; 9: 372-381 [PMID: 22565095 DOI: 10.1038/nrgastro.2012.79]
13. Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, Schwimmer JB. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008; 103: 2263-2271 [PMID: 18684196 DOI: 10.1111/j.1572-0241.2008.02034.x]
14. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49: 608-612 [PMID: 18682312 DOI: 10.1016/j.jhep.2008.06.018]
15. Calori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, Villa M, Bosi E, Ruotolo G, Piemonti L, Perseghin G. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 2011; 54: 145-152 [PMID: 21488080 DOI: 10.1002/hep.24356]
16. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011; 343: d6891 [PMID: 22102439 DOI: 10.1136/bmj.d6891]
17. Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 1724-1745 [PMID: 24587651 DOI: 10.3748/wjg.v20.i7.1724]
18. Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 2007; 191: 182-190 [PMID: 16678831 DOI: 10.1016/j.atherosclerosis]
19. Onat A, Can G, Çiçek G, Ayhan E, Doʇan Y, Kaya H. Fasting, non-fasting glucose and HDL dysfunction in risk of pre-diabetes, diabetes, and coronary disease in non-diabetic adults. Acta Diabetol 2013; 50: 519-528 [PMID: 21769500 DOI: 10.1007/s00592-011-0313-x]
20. Onat A, Aydin M, Can G, Cakmak HA, Köroʇlu B, Kaya A, Ademoʇlu E. Impaired fasting glucose: Pro-diabetic, "atheroprotective" and modified by metabolic syndrome. World J Diabetes 2013; 4: 210-218 [PMID: 24147205]
21. Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7: 691-701 [PMID: 21045794 DOI: 10.1038/nrgastro.2010.172]
22. Onat A, Can G. Enhanced proinflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharm Des 2014; 20: 575-584 [PMID: 23565630 DOI: 10.2174/13 8161282004140213145551]
23. Lerchbaum E, Pilz S, Grammer TB, Boehm BO, Stojakovic T, Obermayer-Pietsch B, März W. The fatty liver index is associated with increased mortality in subjects referred to coronary angiography. Nutr Metab Cardiovasc Dis 2013; 23: 1231-1238 [PMID: 23557879 DOI: 10.1016/j.numecd.2013.02.004]
24. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001; 156: 1-10 [PMID: 11368991 DOI: 10.1016/S0021-9150(01)00500-7]
25. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care 2009; 32 Suppl 1: S13-S61 [PMID: 19118286 DOI: 10.2337/dc09-S013]
26. Rose G, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular Survey Methods. 2nd ed. Geneva, Switzerland: WHO, 1982: 124-127
27. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33 [PMID: 17081293 DOI: 10.1186/1471-230X-6-33]
28. Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M. Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials 2014; 9: 126-133 [PMID: 25514916 DOI: 10.2174/1574887109666141216111143]
29. Okamoto M, Takeda Y, Yoda Y, Kobayashi K, Fujino MA, Yamagata Z. The association of fatty liver and diabetes risk. J Epidemiol 2003; 13: 15-21 [PMID: 12587609 DOI: 10.2188/jea.13.15]
30. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007; 22: 1086-1091 [PMID: 17608855 DOI: 10.1111/j.1440-1746.2006.04781.x]
31. Balkau B, Lange C, Vol S, Fumeron F, Bonnet F. Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol 2010; 10: 56 [PMID: 20529259]
32. Jiang ZY, Xu CY, Chang XX, Li WW, Sun LY, Yang XB, Yu LF. Fatty liver index correlates with non-alcoholic fatty liver disease, but not with newly diagnosed coronary artery atherosclerotic disease in Chinese patients. BMC Gastroenterol 2013; 13: 110 [PMID: 23834773 DOI: 10.1186/1471-230X-13-110]
33. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57: 1357-1365 [PMID: 23175136 DOI: 10.1002/hep.26156]
34. Kotani K, Tsuzaki K, Sakane N. The relationship between gammaglutamyltransferase (GGT), bilirubin (Bil) and small dense lowdensity lipoprotein (sdLDL) in asymptomatic subjects attending a clinic for screening dyslipidaemias. Ann Acad Med Singapore 2014; 43: 216-219 [PMID: 24833073]
35. Rainwater DL, Haffner SM. Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype. Arterioscler Thromb Vasc Biol 1998; 18: 1335-1341 [PMID: 9714142 DOI: 10.1161/01.ATV.18.8.1335]
36. Onat A, Çoban N, Can G, Yüksel M, Karagöz A, Yüksel H, Ademoʇlu E, Erginel-Ünaltuna N. Low "quotient" Lp(a) concentration mediates autoimmune activation and independently predicts cardiometabolic risk. Exp Clin Endocrinol Diabetes 2015; 123: 11-18 [PMID: 25314652]
37. Onat A, Hergenç G, Ozhan H, Kaya Z, Bulur S, Ayhan E, Can G. Lipoprotein(a) is associated with coronary heart disease independent of metabolic syndrome. Coron Artery Dis 2008; 19: 125-131 [PMID: 18418227 DOI: 10.1097/MCA.0b013e3282f399cf]
38. Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of Fatty liver. Endocr Rev 2008; 29: 939-960 [PMID: 18723451 DOI: 10.1210/er.2008-0009]
39. Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. Hepatol Res 2013; 43: 51-64 [PMID: 23332087 DOI: 10.1111/j.1872-034X.2012.01031.x]
40. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121 [PMID: 16012941 DOI: 10.1053/j.gastro.2005.04.014]
41. Hong NS, Kim JG, Lee YM, Kim HW, Kam S, Kim KY, Kim KS, Lee DH. Different associations between obesity and impaired fasting glucose depending on serum gammaglutamyltransferase levels within normal range: a cross-sectional study. BMC Endocr Disord 2014; 14: 57 [PMID: 25015117 DOI: 10.1186/1472-6823-14-57]